|
|
|
|
|
30.10.26 - 11:33
|
Setara Biosciences Announces $90 Million Series A Financing to Advance Precision Medicines for Rare Genetic Diseases and Related Expansion Indications (Business Wire)
|
|
|
Company created following Jazz Pharmaceuticals' acquisition of Actio Biosciences
Setara plans to advance clinical-stage small molecule TRPV4 inhibitor for treatment of Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, along with other early-stage discovery programs
Investor syndicate comprised of leading healthcare investors including Deerfield Management, Canaan, Droia Ventures, EcoR1, Euclidean Capital, and Regeneron Ventures, as well as Jazz PharmaceuticalsSAN DIEGO--(BUSINESS WIRE)--Setara Biosciences, Inc. (Setara), a clinical-stage biotechnology company leveraging genetics to develop precision medicines for severe rare diseases, today announced the completion of a $90 million Series A financing. Setara was formed following the closing of Jazz Pharmaceuticals' acquisition of Actio Biosciences (Actio) for its lead program ABS-1230, an investigational therapy for KCNT1-related epilepsy. Setara intends to advance Actio's remaining pipeline, led by the clinical-stage small molecule T...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.10.26 - 17:42
|
Claritas Rx Appoints Biopharma Commercial Leader Jonathan Witt to Board of Directors (Business Wire)
|
|
|
Former Genentech Senior Vice President Brings More Than 25 Years of Biopharma Experience to Guide Continued Growth and Patient ImpactSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Claritas Rx, the patient journey experts, today announced the appointment of Jonathan Witt to its Board of Directors. Mr. Witt is an accomplished senior executive with more than 25 years of experience in U.S. and global biopharmaceutical roles. He has a proven record of evaluating market opportunities across diverse therapeutic areas, setting development, commercialization, and corporate strategy, building and scaling enterprise capabilities, and transforming organizations to deliver leading customer experiences.
Mr. Witt is the Chief Customer Experience Officer at Jazz Pharmaceuticals, where he leads the global commercial organization's evolution to deliver a seamless, differentiated patient and customer experience across all therapeutic areas.
Before Jazz, Mr. Witt spent nearly 20 years at Genentech, most recently as Senior Vi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
